Virus News and Research

Latest Virus News and Research

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Fluzone® Intradermal (Influenza Virus Vaccine). The file has been accepted by the FDA and an action date is anticipated in the first half of 2011.

From BD (Becton, Dickinson and Company) 14 Sep 2010

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo.

13 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis will be presented at the Annual Congress of the European Respiratory Society, to be held September 18-22 in Barcelona, Spain.

13 Sep 2010

Daiichi Sankyo receives marketing approval for Inavir in Japan

Biota Holdings Limited today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® in Japan. Inavir® is Daiichi Sankyo's brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Octapharma sponsors symposium on inhibitors in Haemophilia A

In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates − i.e. anti-FVIII neutralising antibodies − Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress.

13 Sep 2010

Catch by Gene enters agreement with C&S for HPV test kit

Catch by Gene has entered into an agreement to supply its reagent solutions to C&S Company Ltd commencing immediately in the initial amount of $300,000.

13 Sep 2010

Disinfectant hand gels not effective against Swine flu: Study

According to the latest research published this Sunday, regular use of alcohol-based disinfecting hand gels has little effect on the H1N1 swine flu infection rates. The authors of the study said that the infection is spread by air droplets rather than touch and contact.

12 Sep 2010

Research Roundup: Shifting ER visits to urgent care centers; Evaluating doctors; Medicare Advantage quality ratings

Health Affairs: Many Emergency Department Visits Could Be Managed At Urgent Care Centers And Retail Clinics - Researchers analyzed samples of patient records and found "13.7 percent of all emergency department visits could take place at a retail clinic" - 7.9 percent when hours are restricted - and "an additional 13.4 percent of emergency department visits could take place at a urgent care center—8.9 percent when hours are restricted.

10 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

Numerate awarded new contract by Defense Threat Reduction Agency

Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.

10 Sep 2010

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company's lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.

10 Sep 2010

56% of Australians won’t vaccinate against Swine flu: Survey

Over fifty per cent of Australians were not vaccinated against the swine flu before winter arrived this year, with many of these people deliberately choosing not to be vaccinated.

9 Sep 2010

Researchers discover first compound to activate enzyme telomerase in human body

Sierra Sciences, in collaboration with TA Sciences, Geron Corporation, PhysioAge, and the Spanish National Cancer Research Center (CNIO), has announced the first compound ever discovered that activates the enzyme telomerase in the human body - a critical prerequisite for technology that could arrest or reverse the aging process in humans.

9 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Scientists discover sensor in dendritic cells that recognizes HIV

Dendritic cells are the grand sentinels of the immune system, standing guard 24/7 to detect foreign invaders such as viruses and bacteria, and bring news of the invasion to other immune cells to marshal an attack. These sentinels, however, nearly always fail to respond adequately to HIV, the virus causing AIDS. Now a team of scientists at NYU Langone Medical Center has discovered a sensor in dendritic cells that recognizes HIV, spurring a more potent immune response by the sentinels to the virus.

9 Sep 2010

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream. A new study involving 195 infants in South Africa found that children who were treated with PI and then switched to nevirapine were more likely to maintain virus below the detection threshold of the test than infants who continued to receive PI.

9 Sep 2010

Virus News and Research

Latest Virus News and Research

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

Daiichi Sankyo receives marketing approval for Inavir in Japan

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Octapharma sponsors symposium on inhibitors in Haemophilia A

Catch by Gene enters agreement with C&S for HPV test kit

Disinfectant hand gels not effective against Swine flu: Study

Research Roundup: Shifting ER visits to urgent care centers; Evaluating doctors; Medicare Advantage quality ratings

395 new vaccines being developed for infectious diseases: PhRMA

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Numerate awarded new contract by Defense Threat Reduction Agency

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

56% of Australians won’t vaccinate against Swine flu: Survey

Researchers discover first compound to activate enzyme telomerase in human body

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Scientists discover sensor in dendritic cells that recognizes HIV

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in